Initiator Pharma A/S (SE:INIT)

:INIT

INIT

Initiator Pharma A/S

RESEARCH TOOLSreports

Initiator Pharma A/S (INIT) Price & Analysis

0 Followers

INIT Stock Chart & Stats

kr3.04

-kr0.20(-3.17%)

At close: Mar 06 4:00 PM EST

kr3.04

-kr0.20(-3.17%)

Day’s Range― - ―

52-Week Rangekr2.56 - kr6.90

Previous CloseN/A

Volume47.38K

Average Volume (3M)133.41K

Market Cap

kr210.83M

Enterprise Valuekr120.44M

Total Cash (Recent Filing)kr26.26M

Total Debt (Recent Filing)kr2.15M

Price to Earnings (P/E)―

Beta0.55

Next Earnings

May 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding68,452,890

10 Day Avg. Volume157,519

30 Day Avg. Volume133,406

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)4.31

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet CushionA materially larger equity base than debt provides a durable financial cushion, lowering immediate insolvency risk and giving the company runway to advance clinical programs. This improves negotiating leverage with partners and underpins short-to-medium-term program continuity.

Focused Clinical PipelineConcentrating on sexual dysfunction creates a clear therapeutic niche and regulatory pathway, enabling specialized R&D and clinical trial design. A focused pipeline can attract partners seeking targeted indications and may accelerate licensing or co-development discussions.

Partner/licensing Commercialization StrategyA business model built on partnerships and licensing reduces the need for large commercial infrastructure, making development more capital-efficient. This structural approach can enable faster transitions to revenue via upfronts, milestones, and royalties if partnerships are secured.

Bears Say

Pre-revenue ProfileNo product revenue means the company cannot self-fund operations or de-risk programs through sales. Long-term stability depends on successful clinical outcomes and external financing or partner deals, elevating execution and funding risk for the next 2–6 months and beyond.

Sustained Operating Cash BurnPersistent and sizable negative operating cash flow signals ongoing reliance on external financing. Continued burn at recent levels increases dilution or debt risk, constrains R&D planning, and creates pressure to secure partners or capital to sustain pivotal development programs.

Rising Net Losses And SpendingA sharp step-up in losses reflects increased development spending and raises the threshold for future funding or partner interest. If higher costs do not translate into demonstrable clinical progress or external commitments, the company faces amplified funding and execution risk.

INIT FAQ

What was Initiator Pharma A/S’s price range in the past 12 months?

Initiator Pharma A/S lowest stock price was kr2.56 and its highest was kr6.90 in the past 12 months.

What is Initiator Pharma A/S’s market cap?

Initiator Pharma A/S’s market cap is kr210.83M.

When is Initiator Pharma A/S’s upcoming earnings report date?

Initiator Pharma A/S’s upcoming earnings report date is May 21, 2026 which is in 43 days.

How were Initiator Pharma A/S’s earnings last quarter?

Initiator Pharma A/S released its earnings results on Feb 20, 2026. The company reported -kr0.062 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.062.

Is Initiator Pharma A/S overvalued?

According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Initiator Pharma A/S pay dividends?

Initiator Pharma A/S does not currently pay dividends.

What is Initiator Pharma A/S’s EPS estimate?

Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Initiator Pharma A/S have?

Initiator Pharma A/S has 68,452,890 shares outstanding.

What happened to Initiator Pharma A/S’s price movement after its last earnings report?

Initiator Pharma A/S reported an EPS of -kr0.062 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.933%.

Which hedge fund is a major shareholder of Initiator Pharma A/S?

Currently, no hedge funds are holding shares in SE:INIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Initiator Pharma A/S

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.